Intracranial Therapeutic Delivery Market, By Therapy, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Intracranial Therapeutic Delivery Market size was valued at USD 1,980.32 Million in 2023, expanding at a CAGR of 7.99% from 2024 to 2032.

The intracranial therapeutic delivery market focuses on methods and technologies used to administer treatments directly into the cranial cavity, targeting conditions such as brain tumors, epilepsy, and neurodegenerative disorders. This market encompasses a variety of delivery systems, including implantable devices, infusions, and drug-eluting technologies that optimize therapeutic efficacy and minimize side effects.

Innovations in this field aim to improve patient outcomes through precise targeting, sustained release, and enhanced bioavailability of medications. As research progresses, the market is also seeing developments in gene therapy and biologics for neurological applications. The growing prevalence of neurological disorders and advances in medical technology are key factors driving demand in this sector, making it a critical area of focus in modern healthcare.

Intracranial Therapeutic Delivery Market- Market Dynamics

Increased prevalence of neurological disorders driving demand for targeted therapies.

The increasing prevalence of neurological disorders is a significant driver for the intracranial therapeutic delivery market. As the population ages, conditions such as Alzheimer's, Parkinson's, and multiple sclerosis are becoming more common, necessitating advanced treatment options. According to the CDC, an estimated 1 in 6 adults in the U.S. reported having a neurological condition in 2020. This rising incidence fuels the demand for innovative therapeutic delivery systems that can provide targeted and effective treatments.

Furthermore, greater awareness and early diagnosis contribute to the growing patient pool seeking specialized care. As healthcare systems strive to address these challenges, investments in research and development for novel intracranial delivery methods are expected to expand, creating opportunities for market growth.

Intracranial Therapeutic Delivery Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.99% over the forecast period (2024-2032)

Based on Therapy segmentation, Gene Therapy, was predicted to show maximum market share in the year 2023

Based on Indication segmentation, Multiple Sclerosis was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Intracranial Therapeutic Delivery Market- Segmentation Analysis:

The Global Intracranial Therapeutic Delivery Market is segmented based on Therapy, Indication, and Region.

The market is divided into three categories based on Therapy: Cell-based Therapy, Gene Therapy, and Enzyme Replacement Therapy. Gene Therapy is the most prominent in the intracranial therapeutic delivery market. This approach offers the potential to address the underlying genetic causes of neurological disorders, providing long-term solutions rather than just symptomatic relief. Advances in vector technology and CRISPR gene editing are enhancing the efficacy and safety of gene therapies, making them increasingly viable for conditions like genetic forms of epilepsy and neurodegenerative diseases. The growing focus on personalized medicine further propels the demand for gene therapy, as treatments can be tailored to individual genetic profiles. Overall, its innovative nature and transformative potential position gene therapy as a leading segment in the market.

The market is divided into four categories based on Indication: Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Batten Disease, and Amyotrophic Lateral Sclerosis. Multiple Sclerosis (MS) is the most prominent in the intracranial therapeutic delivery market. MS affects millions globally, leading to significant demand for innovative treatment options that can manage its complex symptoms and slow disease progression. Advances in therapies, including monoclonal antibodies and oral treatments, are enhancing patient outcomes and driving market growth. The increasing prevalence of MS, along with ongoing research into more effective delivery methods, underscores its importance as a focal point for therapeutic development. As awareness and diagnosis improve, the market for MS-related treatments continues to expand, solidifying its position as a dominant segment.

Intracranial Therapeutic Delivery Market- Geographical Insights

North America stands out as the largest region in the intracranial therapeutic delivery market, driven primarily by the presence of leading healthcare companies, advanced research facilities, and a robust regulatory framework. The United States, in particular, accounts for a significant share due to high healthcare expenditure, a strong emphasis on innovation, and an aging population prone to neurological disorders. Additionally, favorable reimbursement policies and a well-established infrastructure for clinical trials support market growth.

The region is also witnessing increased investments in neurological research, which fosters the development of new therapeutic modalities. While Europe and Asia-Pacific are emerging markets with growing demand, North America's established healthcare ecosystem continues to set the pace, making it a focal point for both existing players and new entrants looking to innovate in intracranial therapeutic delivery.

Intracranial Therapeutic Delivery Market- Competitive Landscape:

The intracranial therapeutic delivery market is characterized by intense competition among established players and emerging biotech firms. Key companies like Medtronic and AbbVie dominate with their extensive product portfolios and robust R&D capabilities, focusing on advanced drug delivery systems and innovative therapies for neurological conditions. Additionally, Stryker and Boston Scientific leverage their strong presence in surgical devices to enhance therapeutic outcomes.

Emerging players, such as NeuroRx and Zynerba Pharmaceuticals, are introducing novel treatment modalities, including cannabinoid-based therapies, which diversify the market landscape. Collaboration and strategic partnerships are common as companies seek to accelerate innovation and expand their market reach. Regulatory challenges and the need for clinical validation remain critical hurdles, influencing competitive strategies. Overall, the market is poised for growth as advancements in technology and a deeper understanding of neurological diseases drive new product development.

Recent Developments:

In September 2024, CereVasc's endovascular device has the potential to serve as a novel delivery system for gene therapy directly to the brain, improving treatment efficacy for neurological conditions. By utilizing this approach, aims to enhance targeted therapy while minimizing invasiveness and side effects associated with traditional methods.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Medtronic
AbbVie
Stryker Corporation
Baxter International
Ipsen S.A.
Johnson & Johnson (Ethicon)
NuVasive
NeuroRx
CureVac AG
Boston Scientific
Aesculap
Zynerba Pharmaceuticals
Elekta
Intra-Cellular Therapies

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis
Others

GLOBAL INTRACRANIAL THERAPEUTIC DELIVERY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4050

1. Intracranial Therapeutic Delivery Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Intracranial Therapeutic Delivery Market Snippet by Therapy
- 2.1.2. Intracranial Therapeutic Delivery Market Snippet by Indication
- 2.1.3. Intracranial Therapeutic Delivery Market Snippet by Country
- 2.1.4. Intracranial Therapeutic Delivery Market Snippet by Region
2.2. Competitive Insights

3. Intracranial Therapeutic Delivery Key Market Trends

3.1. Intracranial Therapeutic Delivery Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Intracranial Therapeutic Delivery Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Intracranial Therapeutic Delivery Market Opportunities
3.4. Intracranial Therapeutic Delivery Market Future Trends

4. Intracranial Therapeutic Delivery Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Intracranial Therapeutic Delivery Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Intracranial Therapeutic Delivery Market Landscape

6.1. Intracranial Therapeutic Delivery Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Intracranial Therapeutic Delivery Market - By Therapy

7.1. Overview
- 7.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
- 7.1.2. Cell-based Therapy
- 7.1.3. Gene Therapy
- 7.1.4. Enzyme Replacement Therapy

8. Intracranial Therapeutic Delivery Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 8.1.2. Spinal Muscular Atrophy (SMA)
- 8.1.3. Multiple Sclerosis
- 8.1.4. Batten Disease
- 8.1.5. Amyotrophic Lateral Sclerosis
- 8.1.6. Others

9. Intracranial Therapeutic Delivery Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Intracranial Therapeutic Delivery Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Intracranial Therapeutic Delivery Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.7. Italy
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.7.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.8. United Kingdom
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.9. France
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.10. Russia
  - 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.10.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.11. Netherlands
  - 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.12. Sweden
  - 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.13. Poland
  - 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.13.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.14. Rest of Europe
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Intracranial Therapeutic Delivery Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.6. India
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.7. China
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.8. Japan
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.8.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.9. South Korea
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.11. Thailand
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.12. Indonesia
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Intracranial Therapeutic Delivery Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Intracranial Therapeutic Delivery Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.7. United Arab Emirates
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Intracranial Therapeutic Delivery Industry

10.1. Competitive Dashboard
10.2. Company Profiles
- 10.2.1. Medtronic
- 10.2.2. AbbVie
- 10.2.3. Stryker Corporation
- 10.2.4. Baxter International
- 10.2.5. Ipsen S.A.
- 10.2.6. Johnson & Johnson (Ethicon)
- 10.2.7. NuVasive
- 10.2.8. NeuroRx
- 10.2.9. CureVac AG
- 10.2.10. Boston Scientific
- 10.2.11. Aesculap
- 10.2.12. Zynerba Pharmaceuticals
- 10.2.13. Elekta
- 10.2.14. Intra-Cellular Therapies

11. 360 Degree Analyst View

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us